世界のアルブテロール市場 – 業界動向と2030年までの予測

Request for TOC TOC のリクエスト Speak to Analyst アナリストに相談する Buy Now今すぐ購入 Inquire Before Buying 事前に問い合わせる Free Sample Report 無料サンプルレポート

世界のアルブテロール市場 – 業界動向と2030年までの予測

  • Pharmaceutical
  • Upcoming Report
  • Jun 2023
  • Global
  • 350 ページ
  • テーブル数: 220
  • 図の数: 60

世界のアルブテロール市場

Market Size in USD Billion

CAGR :  % Diagram

Diagram 予測期間
2023 –2030
Diagram 市場規模(基準年)
USD 4,587.68 Million
Diagram Market Size (Forecast Year)
USD 7,984.37 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Mylan
  • CIpal
  • Sun Pharmaceutical Industries
  • Amneal pharmaceutical
  • SUNOVION

>世界のアルブテロール市場、疾患別(喘息、慢性閉塞性肺疾患(COPD)、その他)、製品タイプ別(アルブテロール硫酸塩吸入液 0.083%、アルブテロール硫酸塩吸入液 0.042%、アルブテロール硫酸塩吸入液 0.021%、アルブテロール硫酸塩吸入液 0.5%、その他)、タイプ別(ジェネリック、ブランド)、用量別(経口、吸入、その他)、エンドユーザー別(病院、専門クリニック、在宅医療、その他)、流通チャネル別(直接入札、病院薬局、小売薬局、オンライン薬局、その他)– 2030年までの業界動向と予測。

アルブテロール市場

 アルブテロール市場分析と規模

喘息、慢性閉塞性肺疾患(COPD)、気管支炎などの呼吸器疾患の罹患率の増加により、アルブテロール市場の成長が促進されました。アルブテロールは、喘息や慢性閉塞性肺疾患などの肺疾患によって引き起こされる喘鳴、呼吸困難、胸の圧迫感、咳の予防と治療に使用されます。                                

データブリッジマーケットリサーチは、2022年に45億8,768万米ドルだったアルブテロール市場は、2030年までに79億8,437万米ドルに急増し、予測期間中に6.80%のCAGRを達成すると予測しています。これは、市場価値を示しています。アルブテロール市場の投薬セグメントでは、「経口」が主流であり、これは臨床医と患者の間で2番目に好まれる投与方法であるためです。データブリッジマーケットリサーチがまとめた市場レポートには、市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、詳細な専門家の分析、患者の疫学、パイプライン分析、価格分析、規制の枠組みも含まれています。

 アルブテロール市場の範囲とセグメンテーション

レポートメトリック

詳細

予測期間

2023年から2030年

基準年

2022

歴史的な年

2021 (2015~2020年にカスタマイズ可能)

定量単位

売上高(百万米ドル)、販売数量(個数)、価格(米ドル)

対象セグメント

喘息、慢性閉塞性肺疾患(COPD)、その他)、製品タイプ(硫酸アルブテロール吸入液 0.083%、硫酸アルブテロール吸入液 0.042%、硫酸アルブテロール吸入液 0.021%、硫酸アルブテロール吸入液 0.5%、その他)、タイプ(ジェネリック、ブランド)、用量(経口、吸入、その他)、エンドユーザー(病院、専門クリニック、在宅医療、その他)、流通チャネル(直接入札、病院薬局、小売薬局、オンライン薬局、その他)

対象国

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Mylan N.V.(U.S.),Cipla Inc(India), Sun Pharmaceutical Industries Ltd.(India), Amneal pharmaceutical Inc.(U.S.), SUNOVION, Akron Inc.(U.S.), GlaxoSmithKline PLC.(U.K.), TevaPharmaceuticalsIndustriesLtd.(U.S.),Aurobindo(India),ZydusPharmaceutical(India),LUPIN(India),AstraZeneca(U.K.),NovartisAG(Switzerland), Boehringer Ingelheim Pharmaceuticals(Germany), Merck & Co., Inc.(U.S.), Perrigo Company plc(Ireland), Hikma Pharmaceuticals PLC(U.K.), Amphastar Pharmaceuticals, Inc. (U.S.), Dr. Reddy's Laboratories Ltd.(India), Pfizer Inc.(U.S.), Apotex Inc.(Canada)

Market Opportunities

  • Technological Advancement
  •  Expansion of Distribution Channels
  • Combination Therapies

Market Definition

Albuterol, also known as salbutamol, is a bronchodilator medication that belongs to a class of drugs called beta-agonists. It is primarily used for the treatment of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and other obstructive airway diseases. Albuterol works by relaxing and opening up the airways, which helps to relieve symptoms such as wheezing, shortness of breath, coughing, and chest tightness..            

 Albuterol Market Dynamics

Drivers

  • Increasing Prevalence of Respiratory Diseases

The global prevalence of respiratory diseases such as asthma, COPD, and bronchitis continues to rise. This presents a significant opportunity for the albuterol market as albuterol is a commonly prescribed medication for these conditions. The growing patient population and the need for effective management of respiratory diseases create a demand for albuterol medications.

  • Growing Awareness and Diagnosis

There has been a significant improvement in the awareness and diagnosis of respiratory diseases in recent years. Better access to healthcare facilities, increased awareness campaigns, and advancements in diagnostic techniques have led to early detection and improved management of respiratory conditions. As a result, more patients are being diagnosed and prescribed albuterol for their treatment.

  • Lifestyle Changes

Modern lifestyles characterized by sedentary habits, poor dietary choices, and exposure to environmental pollutants contribute to the development and exacerbation of respiratory diseases. Factors such as smoking, occupational hazards, and urbanization lead to an increased risk of respiratory conditions. Albuterol plays a crucial role in managing the symptoms and providing relief to individuals affected by these lifestyle-related respiratory disorders.  

  • Government Initiatives and Healthcare Expenditure

Governments and healthcare organizations worldwide are actively involved in addressing the burden of respiratory diseases. They promote awareness campaigns, support research and development activities, and allocate healthcare budgets for the management of respiratory conditions. These initiatives contribute to increased access to albuterol medications, driving market growth

Opportunities

  • Combination Therapies

Combination therapies that incorporate albuterol along with other respiratory medications, such as corticosteroids or long-acting bronchodilators, offer opportunities for market growth. These combination therapies provide enhanced efficacy, convenience, and simplified treatment regimens for patients. Manufacturers focusing on developing and marketing combination therapies can cater to the evolving needs of healthcare providers and patients, and acting as an opportunity for the market expansion

  • Technological Advancements

Continuous advancements in drug delivery systems and devices provide opportunities for the albuterol market. Innovations in inhalers, such as the development of metered-dose inhalers (MDIs), dry powder inhalers (DPIs), and smart inhalers, enhance the convenience, efficiency, and patient compliance of albuterol treatments. Companies investing in research and development to improve drug delivery systems can gain a competitive edge and capture a larger market share

Restraints/Challenges

  • Stringent Regulatory Requirements:

The development and commercialization of albuterol medications are subject to stringent regulatory requirements imposed by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Meeting these regulatory standards involves substantial time, resources, and costs for manufacturers. Compliance with complex regulations can pose challenges for market players and potentially delay product launches or limit market entry for new entrants.

  • Side Effects and Safety Concerns:

Although albuterol is generally considered safe when used as directed, it can have potential side effects such as increased heart rate, tremors, and nervousness. Rare but severe adverse reactions can also occur, such as allergic reactions or paradoxical bronchospasm. Safety concerns associated with albuterol use may impact patient perception and acceptance, leading to a reluctance in using the medication or seeking alternative treatment options.

This  albuterol market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Albuterol Market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Development

  • In March 2021, Sandoz Inc. announced the in-licensing of commercial distribution rights to the brand and authorized generic of respiratory inhalation medicine Proventil HFA (albuterol sulfate) Inhalation Aerosol from Kindeva Drug Delivery, a global contract development and manufacturing organization supplying the product. Our albuterol sulfate authorized generic is immediately available to patients in the US.
  • In August 2020, LUPIN announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Albuterol Sulfate Inhalation Aerosol, 90 mcg (base)/actuation, a generic version of ProAir HFA. Lupin’s generic Albuterol Sulphate MDI will be manufactured at its Indore (Unit III) facility in India

Global Albuterol Market Scope

The  albuterol market is segmented on the basis of disease, product type, type, dosage, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease

  • Asthma
  • chronic obstructive pulmonary disease (COPD)
  • Others

 Product Type

  • Albuterol Sulfate Inhalation Solution 0.083%
  • Albuterol Sulfate Inhalation Solution 0.042%
  • Albuterol Sulfate Inhalation Solution 0.021%
  • Albuterol Sulfate Inhalation Solution 0.5%
  • Others

Type

  • Generic
  • Branded

Dosage

  • Oral
  • Inhalations
  • Others

End User

Distribution Channel

  • Direct Tender
  • Hospital Pharmacy
  •  Retail Pharmacy
  •  Online Pharmacy,
  •  Others

 Albuterol Market Regional Analysis/Insights

The albuterol market is analysed and market size insights and trends are provided by country, diseases, product type, type, dosage, end-users and distribution channel as referenced above.

The countries covered in the  albuterol market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the albuterol market because of the strong base of healthcare facilities, strong presence of major players in the market, increases cases of respiratory diseases such as asthma or COPD and the rising number of research activities in this region.   

Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The albuterol market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Albuterol Market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Albuterol Market. The data is available for historic period 2010-2020.

Competitive Landscape and Albuterol Market Share Analysis

The albuterol market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to albuterol market.

Some of the major players operating in the albuterol market are:

  • マイランNV(米国)
  • CIpal Inc(インド)
  •  サン・ファーマシューティカル・インダストリーズ(インド)
  • アムニール製薬株式会社(米国)
  •  SUNOVION、アクロン社(米国)
  •  グラクソ・スミスクラインPLC(英国)
  •  テバ・ファーマシューティカルズ・インダストリーズ(米国)
  •  オーロビンド(インド)
  •  ザイダス製薬(インド)
  • LUPIN(インド)
  • アストラゼネカ(英国)
  • ノバルティスAG(スイス)
  •  ベーリンガーインゲルハイム製薬(ドイツ)
  • メルク社(米国)
  • ペリゴ カンパニー plc(アイルランド)
  • ヒクマ・ファーマシューティカルズPLC(英国)
  • アンファスター・ファーマシューティカルズ社(米国)
  • ドクター・レディーズ・ラボラトリーズ社(インド)
  • ファイザー社(米国)
  • アポテックス株式会社(カナダ)


SKU-

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

  • インタラクティブなデータ分析ダッシュボード
  • 成長の可能性が高い機会のための企業分析ダッシュボード
  • カスタマイズとクエリのためのリサーチアナリストアクセス
  • インタラクティブなダッシュボードによる競合分析
  • 最新ニュース、更新情報、トレンド分析
  • 包括的な競合追跡のためのベンチマーク分析のパワーを活用
デモのリクエスト

調査方法

データ収集と基準年分析は、大規模なサンプル サイズのデータ​​収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

The market is segmented based on ,  By Diseases (Asthma, Chronic Obstructive Pulmonary Disease (COPD), Others), Product Type (Albuterol Sulfate Inhalation Solution 0.083%, Albuterol Sulfate Inhalation Solution 0.042%, Albuterol Sulfate Inhalation Solution 0.021%, Albuterol Sulfate Inhalation Solution 0.5%, Others), Type (Generic, Branded), Dosage (Oral, Inhalations, Others), End-Users (Hospitals, Specialty Clinics, Home Healthcare, Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2030. .
The Global Albuterol Market size was valued at USD 4587.68 USD Million in 2022.
The Global Albuterol Market is projected to grow at a CAGR of 6.8% during the forecast period of 2023 to 2030.
The major players operating in the market include Mylan, CIpal, Sun Pharmaceutical Industries, Amneal pharmaceutical, SUNOVION, Akron, GlaxoSmithKline, Teva Pharmaceuticals Industries, Aurobindo, Zydus Pharmaceutical, LUPIN, AstraZeneca, Novartis, Boehringer Ingelheim Pharmaceuticals, Merck & Co., Perrigo Company, Hikma Pharmaceuticals, Amphastar Pharmaceuticals, Dr. Reddy's Laboratories, Pfizer, Apotex.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..